吸入抗结核药物治疗肺结核的研究进展

doi:10.11958/20212611

天津医药 ›› 2022, Vol. 50 ›› Issue (9): 998-1001.doi: 10.11958/20212611

吸入抗结核药物治疗肺结核的研究进展

叶静(), 于洪志(), 邵红霞, 武俊平

天津市海河医院,天津大学海河医院结核科,国家中医药管理局传染病重点研究室（邮编300350）

收稿日期:2021-11-22 修回日期:2022-05-02 出版日期:2022-09-15 发布日期:2022-09-05
通讯作者: 于洪志 E-mail:153607477@qq.com;13512205663@163.com
作者简介:叶静（1983）,女,主治医师,主要从事结核病的临床治疗方面研究。E-mail： 153607477@qq.com
基金资助:
2021年度天津市科技计划项目(20JCYBJC01250);2019年度天津市津南区科技计划项目(20200112)

Research progress of inhaled anti-tuberculous drugs in the treatment of pulmonary tuberculosis

YE Jing(), YU Hongzhi(), SHAO Hongxia, WU Junping

Department of Tuberculosis, Haihe Hospital, Tianjin University, China Key Research Laboratory for Infectious Disease Prevention for State Administration of Traditional Chinese Medicine, Tianjin 300350, China

Received:2021-11-22 Revised:2022-05-02 Published:2022-09-15 Online:2022-09-05
Contact: YU Hongzhi E-mail:153607477@qq.com;13512205663@163.com

叶静, 于洪志, 邵红霞, 武俊平. 吸入抗结核药物治疗肺结核的研究进展[J]. 天津医药, 2022, 50(9): 998-1001.

YE Jing, YU Hongzhi, SHAO Hongxia, WU Junping. Research progress of inhaled anti-tuberculous drugs in the treatment of pulmonary tuberculosis[J]. Tianjin Medical Journal, 2022, 50(9): 998-1001.

摘要/Abstract

摘要：

吸入抗结核药物治疗支气管结核已取得较好的效果。但雾化药物微粒直径过大,药物分布不均匀使其不能用于肺组织结核的患者。近年随着药物载体研究的深入,以吸入的方式到达肺组织的剂型不断被成功研发,其具有良好的安全性和有效性。该文就吸入抗结核药物治疗肺组织结核的研究进展进行综述。

关键词: 结核,肺, 抗结核药, 吸入, 载药技术

Abstract:

Inhalation of antituberculous drugs in the treatment of pulmonary tuberculosis has achieved good results in patients with bronchial tuberculosis. However, the diameter of atomized drug particles is too large and the drug distribution is uneven, so that it can not be used for patients with alveolar tissue tuberculosis. In recent years, with the in-depth development of follow-up drug carriers, it is possible to apply antituberculous drugs to patients with alveolar tissue tuberculosis by inhalation, which have good safety and effectiveness. This paper reviews the research progress of inhaled antituberculous drugs in the treatment of alveolar tissue tuberculosis.

Key words: tuberculosis,pulmonary, antitubercular agents, inhalation, drug delivery

中图分类号:

R446.5

参考文献 35

[1]	中华人民共和国国家卫生和计划生育委员会. 中华人民共和国卫生行业标准:肺结核诊断:WS 288-2017[S]. 北京: 国家卫生和计划生育委员会, 2017:1-4.
	State Health and Family Planning Commission of the People's Republic of China. Diagnosis of pulmonary tuberculosis Health industry Standard of the People's Republic of China:Diagnosis of pulmonary tuberculosis:WS 288-2017[S]. Beijing: National Health and Family Planning Commission, 2017:1-4.
[2]	MIRZAYEV F, VINEY K, LINH N N, et al. World Health Organization recommendations on the treatment of drug-resistant tuberculosis,2020 update[J]. Eur Respir J, 2021, 57(6):2003300. doi: 10.1183/13993003.03300-2020.
[3]	World Health Organization(WHO). Global Tuberculosis Report 2021[EB/OL]. (2021-10-14)[2021-11-22]. https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021.
[4]	任成山, 林辉, 杨仕明. 结核病的流行特征与耐多药的窘迫及其策略[J/CD]. 中华肺部疾病杂志(电子版), 2019, 12(3):269-274.
	REN C S, LIN H, YANG S M. Epidemiological characteristics of tuberculosis and distress and strategies of multidrug resistance[J/CD]. China J Lung Dis(Electronic Edition), 2019, 12(3):269-274. doi: 10.3877/cma.j.issn.1674-6902.2019.03.001.
[5]	MACNEIL A, GLAZIOU P, SISMANIDIS C, et al. Global epidemiology of tuberculosis and progress toward meeting global targets-worldwide,2018[J]. MMWR Morb Mortal Wkly Rep, 2020, 69(11):281-285. doi: 10.15585/mmwr.mm6911a2.
[6]	SHAH I, POOJARI V, MESHRAM H. Multi-drug resistant and extensively-drug resistant tuberculosis[J]. Indian J Pediatr, 2020, 87(10):833-839. doi: 10.1007/s12098-020-03230-1.
[7]	URBANOWSKI M E, ORDONEZ A A, RUIZ-BEDOYA C A, et al. Cavitary tuberculosis:the gateway of disease transmission[J]. Lancet Infect Dis, 2020, 20(6):e117-e128. doi: 10.1016/S1473-3099(20)30148-1.
[8]	BASSETTI M, VENA A, RUSSO A, et al. Inhaled liposomal antimicrobial delivery in lung infections[J]. Drugs, 2020, 80(13):1309-1318. doi: 10.1007/s40265-020-01359-z.
[9]	王思思. 雾化吸入抗菌药物辅助治疗呼吸系统感染性疾病的有效性及安全性的Meta分析[D]. 天津: 天津医科大学, 2020.
	WANG S S. Efficacy and safety of aerosolized inhaled antibacterials in the adjuvant treatment of respiratory infection:A Meta-analysis[D]. Tianjin: Tianjin Medical University, 2020.
[10]	SHAH S, GHETIYA R, SONIWALA M, et al. Development and optimization of inhalable levofloxacin nanoparticles for the treatment of tuberculosis[J]. Curr Drug Deliv, 2021, 18(6):779-793. doi: 10.2174/1567201817999201103194626.
[11]	KHADKA P, HILL P C, ZHANG B, et al. A study on polymorphic forms of rifampicin for inhaled high dose delivery in tuberculosis treatment[J]. Int J Pharm, 2020, 587:119602. doi: 10.1016/j.ijpharm.2020.119602.
[12]	MOMIN M, TUCKER I G, DAS S C. The influence of storage relative humidity on aerosolization of co-spray dried powders of hygroscopic kanamycin with the hydrophobic drug rifampicin[J]. Drug Dev Ind Pharm, 2019, 45(7):1205-1213. doi: 10.1080/03639045.2019.1607869.
[13]	HE Y, LIANG Y, HAN R, et al. Rational particle design to overcome pulmonary barriers for obstructive lung diseases therapy[J]. J Control Release, 2019, 314:48-61. doi: 10.1016/j.jconrel.2019.10.035.
[14]	莫胜林, 蒋忠胜. 气管支气管结核诊治新进展[J]. 重庆医学, 2021, 50(11):1927-1931.
	MO S L, JIANG Z S. New progress in diagnosis and treatment of tracheobronchial tuberculosis[J]. Chongqing Med, 2021, 50(11):1927-1931. doi: 10.3969/j.issn.1671-8348.2021.11.028.
[15]	中华医学会结核病学分会,《中华结核和呼吸杂志》编辑委员会. 气管支气管结核诊断和治疗指南(试行)[J]. 中华结核和呼吸杂志, 2012, 35(8):581-587.
	The tuberculosis branch of Chinese Medicine Association, Editorial Committee of Chinese Journal of Tuberculosis and Respiratory Diseases. Guidelines for the diagnosis and treatment of tracheobronchial tuberculosis(trial)[J]. Chin J Tuberc Respir Dis, 2012, 35(8):581-587. doi: 10.3760/cma.j.issn.1001-0939.2012.08.007.
[16]	曾丽娟, 张洁. 抗结核药物不同给药途径的研究进展[J]. 东南国防医药, 2018, 20(5):532-534.
	ZENG L J, ZHANG J. Research progress of different routes of administration of antituberculous drugs[J]. Southeast National Defense Medicine, 2018, 20(5):532-534. doi: 10.3969/j.issn.1672-271X.2018.05.019.
[17]	陈玥龙, 戴枥湾, 李一诗, 等. 气管支气管结核治疗进展[J]. 重庆医科大学学报, 2020, 45(6):714-717.
	CHEN Y L, DAI L W, LI Y S, et al. Progress in treatment of tracheobronchial tuberculosis[J]. Journal of Chongqing Medical University, 2020, 45(6):714-717. doi: 10.13406/j.cnki.cyxb.002368.
[18]	THAKUR A K, CHELLAPPAN D K, DUA K, et al. Patented therapeutic drug delivery strategies for targeting pulmonary diseases[J]. Expert Opin Ther Pat, 2020, 30(5):375-387. doi: 10.1080/13543776.2020.1741547.
[19]	SHARMA S. Emerging treatment trends in pediatric TB[J]. Indian J Tuberc, 2019, 66(1):214-217. doi: 10.1016/j.ijtb.2019.02.010.
[20]	SHARMA S, SINGHAL R, SARIN R, et al. Emerging trends in microbiological diagnostics in children[J]. Indian J Tuberc, 2019, 66(4):549-554. doi: 10.1016/j.ijtb.2019.11.007.
[21]	WYSZOGRODZKA-GAWEł G, DOROżYńSKI P, GIOVAGNOLI S, et al. An inhalable theranostic system for local tuberculosis treatment containing an isoniazid loaded metal organic framework Fe-MIL-101-NH2-from raw mof to drug delivery system[J]. Pharmaceutics, 2019, 11(12):687. doi: 10.3390/pharmaceutics11120687.
[22]	GRIFFITH D E, EAGLE G, THOMSON R, et al. Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (convert). A prospective,open-label,randomized study[J]. Am J Respir Crit Care Med, 2018, 198(12):1559-1569. doi: 10.1164/rccm.201807-1318OC.
[23]	BRAUNSTEIN M, HICKEY A J, EKINS S. Why Wait? The case for treating tuberculosis with inhaled drugs[J]. Pharm Res, 2019, 36(12):166. doi: 10.1007/s11095-019-2704-6.
[24]	SANKHE K, KHAN T, BHAVSAR C, et al. Selective drug deposition in lungs through pulmonary drug delivery system for effective management of drug-resistant TB[J]. Expert Opin Drug Deliv, 2019, 16(5):525-538. doi: 10.1080/17425247.2019.1609937.
[25]	PHAM D D, GRÉGOIRE N, COUET W, et al. Pulmonary delivery of pyrazinamide-loaded large porous particles[J]. Eur J Pharm Biopharm, 2015, 94:241-250. doi: 10.1016/j.ejpb.2015.05.021.
[26]	MEHANNA M M, MOHYELDIN S M, ELGINDY N A. Rifampicin-carbohydrate spray-dried nanocomposite:A futuristic multiparticulate platform for pulmonary delivery[J]. Int J Nanomedicine, 2019, 14:9089-9112. doi: 10.2147/IJN.S211182.
[27]	向海滨. 利福喷丁/聚乳酸-羟基乙酸纳米粒的制备及体外释药特性研究[D]. 新疆: 新疆医科大学, 2020.
	XIANG H B. Preparation of rifapentine loaded poly(lactic-co-glycolic acid) nanoparticles and characteristics of drug release in vitro[D]. Xinjiang: Xinjiang Medical University, 2020.
[28]	ROJANARAT W, NAKPHENG T, THAWITHONG E, et al. Inhaled pyrazinamide proliposome for targeting alveolar macrophages[J]. Drug Deliv, 2012, 19(7):334-345. doi: 10.3109/10717544.2012.721144.
[29]	SRICHANA T, RATANAJAMIT C, JUTHONG S, et al. Evaluation of proinflammatory cytokines and adverse events in healthy volunteers upon inhalation of antituberculosis drugs[J]. Biol Pharm Bull, 2016, 39(11):1815-1822. doi: 10.1248/bpb.b16-00354.
[30]	OLIVEIRA P M, MATOS B N, PEREIRA P, et al. Microparticles prepared with 50-190 kDa chitosan as promising non-toxic carriers for pulmonary delivery of isoniazid[J]. Carbohydr Polym, 2017, 174:421-431. doi: 10.1016/j.carbpol.2017.06.090.
[31]	LUDMYLLA C, SUSANA R, ANA M R, et al. Inhalable chitosan microparticles for simultaneous delivery of isoniazid and rifabutin in lung tuberculosis treatment[J]. Drug Dev Ind Pharm, 2019, 45(8):1313-1320. doi: 10.1080/03639045.2019.1608231.
[32]	黄洁云. 载利福喷丁与利奈唑胺聚乳酸-羟基乙酸缓释微球肺部靶向给药系统的研究[D]. 太原: 山西医科大学, 2017.
	HUANG J Y. Study on rifapentine-linezolid-loaded plga microspheres for lung targeting drug delivery[D]. Taiyuan: Shanxi Medical University, 2017.
[33]	SHKURUPY V A, CHERDANTSEVA L A, KOVNER A V, et al. Structural changes in the lungs and liver of mice with experimental tuberculosis treated with liposome-encapsulated dextrazide[J]. Bull Exp Biol Med, 2020, 168(5):654-657. doi: 10.1007/s10517-020-04773-1.
[34]	GRENHA A, ALVES A D, GUERREIRO F, et al. Inhalable locust bean gum microparticles co-associating isoniazid and rifabutin:Therapeutic assessment in a murine model of tuberculosis infection[J]. Eur J Pharm Biopharm, 2020, 147:38-44. doi: 10.1016/j.ejpb.2019.11.009.
[35]	TAN Z M, LAI G P, PANDEY M, et al. Novel approaches for the treatment of pulmonary tuberculosis[J]. Pharmaceutics, 2020, 12(12):1196. doi: 10.3390/pharmaceutics12121196.

吸入抗结核药物治疗肺结核的研究进展

Research progress of inhaled anti-tuberculous drugs in the treatment of pulmonary tuberculosis

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献 35

相关文章 11

编辑推荐

Metrics

本文评价

[1]	刘斌, 杨龙, 李文莉, 邵宁宁, 董津睿. 小胶质细胞铁死亡在烟雾吸入性脑损伤中的作用机制探讨[J]. 天津医药, 2024, 52(8): 791-797.
[2]	李树华, 赵小龙, 邓伟, 蒋振华. N-乙酰半胱氨酸雾化吸入治疗急性鼻窦炎的临床疗效[J]. 天津医药, 2020, 48(12): 1201-1204.
[3]	李和林 1,2，吕琪 2，肖培欣 2，朱双龙 3，刘子泉 2，刘洪琪 2△. 西维来司钠对烟雾吸入性肺损伤大鼠早期炎症反应的影响[J]. 天津医药, 2017, 45(9): 916-919.
[4]	朱何涛 1，2，朱博 1，高天阳 1，张琳 3，邓晓磊 4，张西峰 2△. 经皮微创手术治疗腰椎结核的中远期疗效观察[J]. 天津医药, 2017, 45(6): 614-619.
[5]	汪芳俊，胡建华，李洪琼，等.. 右美托咪定对七氟醚麻醉患者苏醒呼末七氟醚浓度的影响[J]. 天津医药, 2016, 44(8): 1036-1039.
[6]	王国武，李超，胡啸玲. 不同浓度七氟醚对人前列腺癌细胞增殖与侵袭能力的影响[J]. 天津医药, 2016, 44(2): 159-161.
[7]	贺克强,潘建辉,谢志琼,王瑞婷. 七氟烷后处理对体外循环下心脏瓣膜置换术患者肺功能的影响[J]. , 2013, (7): 0-646 .
[8]	罗婧岩. 布地奈德吸入与穴位贴敷治疗儿童哮喘75例临床观察[J]. , 2012, 40(4): 403-404 .
[9]	万玉峰. 呼出气一氧化氮与慢性咳嗽吸入糖皮质激素治疗疗效的关系[J]. , 2012, 40(11): 1118-1120 .
[10]	肖艳英1 ,常业恬1 ,冉珂2 ,李双凤1 . Mito-KATP在七氟醚延迟预处理减轻大鼠心肌缺血再灌注氧化损伤中的作用[J]. , 2011, 39(8): 739-742 .
[11]	孙夫强1 ,段洋2 ,王林2 . 新生儿持续性肺动脉高压的吸入一氧化氮治疗[J]. , 2010, 38(5): 0-0 .